Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIGARD in radio-recurrent oligo-metastatic hormone/castrate sensitive prostate cancer
NCT06654336Phase 2Recruiting
- Sponsor
- Ontario Clinical Oncology Group
- Start
- May 2026
- Primary completion
- Apr 2031
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by Ontario Clinical Oncology Group. Primary endpoint: Composite Progression-Free Survival at 36 months. Started May 2026; status: recruiting.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06654336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654336.